SCHEMBL4501614

SCHEMBL4501614

CCC(CO)Nc1nc(NCc2ccncc2)c2ncn(C(C)C)c2n1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDK2 P24941 12/20 1.00
CDK1 P06493 10/20 1.00
CCNE1 P24864 8/20 1.00
CDK7 P50613 7/20 1.00
CCNB1 P14635 7/20 1.00
CDK4 P11802 5/20 1.00
CCND1 P24385 5/20 1.00
CCNH P51946 5/20 1.00
MAPK1 P28482 4/20 1.00
CCNK O75909 8/20 0.89
CDK12 Q9NYV4 8/20 0.89
CDK5 Q00535 7/20 0.84
CDK9 P50750 6/20 0.84
DYRK1A Q13627 5/20 0.84
CCNA2 P20248 5/20 0.84
CCNA1 P78396 4/20 0.84
CDK5R1 Q15078 4/20 0.84
CCNB2 O95067 3/20 0.84
CCNB3 Q8WWL7 3/20 0.84
CSNK1D P48730 2/20 0.84

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3877470 1.00 CDK2 (1.00) CDK2CDK1CCNE1CDK7CCNB1
(Rs)-Roscovitine SCHEMBL15163619 0.91 CDK1 (1.00) CDK2CDK1CCNE1CDK7CCNB1
(S)-Roscovitine SCHEMBL29415376 0.91 CDK1 (1.00) CDK2CDK1CCNE1CDK7CCNB1
Seliciclib SCHEMBL94728 0.91 CDK1 (1.00) CDK2CDK1CCNE1CDK7CCNB1
(S)-Roscovitine SCHEMBL2907488 0.91 CDK1 (1.00) CDK2CDK1CCNE1CDK7CCNB1
(Rs)-Roscovitine SCHEMBL172593 0.91 CDK1 (1.00) CDK2CDK1CCNE1CDK7CCNB1
SCHEMBL6016706 0.90 CDK1 (1.00) CDK2CDK1CCNE1CDK7CCNB1
SCHEMBL17628584 0.89 CDK2 (1.00) CDK2CDK1CCNE1CDK7CCNB1
SCHEMBL13633363 0.89 CDK2 (1.00) CDK2CDK1CCNE1CDK7CCNB1
SCHEMBL28461441 0.89 CDK1 (0.80) CDK2CDK1CCNE1CDK7CCNB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7612079-B2 2,6,9-substituted purine derivatives and their use in the treatment of proliferative disorders CYCLACEL LIMITED (GB) 2009-11-03 US disclosed
EP-1399446-B1 2,6,9-SUBSTITUTED PURINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF PROLIFERATIVE DISORDERS CYCLACEL LTD (GB) 2005-08-03 EP disclosed
US-20050009846-A1 2,6,9-Substituted purine derivatives and their use in the treatment of proliferative disorders CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2005-01-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050009846-A1 2,6,9-Substituted purine derivatives and their use in the treatment of proliferative disorders TYMP, PNP, IMPDH1 CDK2 40/4885CDK1 117/4885CCNE1 390/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.